Cipla has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus (Photo source: NDTV Profit) Show Quick Read Summary is AI Generated. Newsroom Reviewed

Drugmaker Cipla on Wednesday said it has launched a medication for managing obesity and type-2 diabetes mellitus. The company has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus, two of the country's most pressing health challenges, the Mumbai-based drugmaker said in a regulatory filing.

The company has the rights to distribute and promote Yurpeak -- the second brand of Lilly's tirzepatide in India, after Lilly received DCGI approval, it added. Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polyp

See Full Page